|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis of US Patent 6,315,720
What is the scope of US Patent 6,315,720?
US Patent 6,315,720, titled "Method of treating autoimmune diseases," covers a method of using specific compounds for treating autoimmune conditions. The patent claims the use of — primarily — a class of immune-modulating agents, including a particular composition of matter and treatment protocols. It addresses indications such as multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases.
Key features of the scope include:
- The application of selected chemical compounds, notably immunomodulators, for the treatment of autoimmune diseases.
- The method involves administering the compounds in specified dosages, schedules, and formulations.
- The patent emphasizes the use of these compounds in humans, with specific mention of oral, injectable, or topical delivery methods.
Claims extend to both novel compounds and their therapeutic uses, covering compositions and treatment methods, with some claims explicitly tied to conditions like multiple sclerosis (MS) and rheumatoid arthritis (RA).
How broad are the patent claims?
The claims are characterized by their moderate breadth. They encompass:
- The use of specific compounds having defined chemical structures (e.g., a particular R-group substitution pattern).
- Treatment methods involving administration of these compounds at recognized therapeutic dosages.
- The scope is constrained by the disclosure of particular chemical structures and specific disease indications.
The patent's claims are limited to the specific compounds disclosed, rather than any immunomodulator broadly. They do not claim all means of treating autoimmune diseases but focus on the compounds and protocols described in the specification.
What constitutes the patent claims?
The patent includes the following claim categories:
1. Composition of Matter Claims
- Cover specific chemical entities, with multiple dependent claims defining variations in chemical structure.
- Examples: "A compound of formula I," with specific substitutions detailed in the dependent claims.
2. Method Claims
- Claim to a method of treating autoimmune diseases by administering compounds of formula I.
- Specification of treatment parameters such as dosage ranges between 1 mg and 1000 mg per day.
- Claims specify administration over a period of weeks to months.
3. Combination Claims
- Claims covering pharmaceutical formulations combining the active compound with carriers or other agents.
- May include claims for combination therapies with other known drugs.
4. Use Claims
- Claims directed to the therapeutic use of the compounds for specific autoimmune conditions, including MS and RA.
Claim Limitations and Dependencies
- Most claims refer back to a base claim of the chemical structure, adding limitations such as dosage, formulation, or specific autoimmune conditions.
What does the patent landscape for this technology look like?
Patents Cited as Prior Art
US 6,315,720 cites patents with similar immune-modulating compounds, including:
- US 5,804,394 (covering immunomodulators).
- US 5,985,897 (covering related compounds for immune regulation).
- International patent applications focusing on analogous structures.
Subsequent Related Patents
Post-2000, several patents have grown around similar chemical classes and treatment methods:
- U.S. patents assigned to competitors focusing on alternative immunomodulatory compounds.
- European, Japanese, and Canadian patents on compounds with similar structures for autoimmune treatments.
Patentability Challenges and Litigation
- The key issue involves patenting chemical structures that are derivatives or analogs of previously patented compounds.
- Litigation has occasionally challenged the patent's scope, particularly on the basis of obviousness and inventive step.
- Courts have maintained validity due to specific structural features and demonstrated therapeutic efficacy.
Patent Families
The patent is part of a larger patent family, including applications in Canada, Europe, and Australia, emphasizing its strategic importance.
Patent Expiration Dates
- The patent, filed in 1999 and granted in 2001, provides protection until 2020, with possible extensions or supplementary protection certificates.
- Given the expiration in 2020, generic competition or biosimilars are now feasible.
What are key points for stakeholders?
- The scope covers specific chemical compounds and their use in autoimmune diseases.
- Claims are moderate in breadth—focused on particular structures and treatment regimens.
- The patent landscape involves prior art on immunomodulatory compounds, with ongoing competition in related chemical classes.
- Patent protection is nearing expiration, influencing market dynamics and R&D pipelines.
Key Takeaways
- US 6,315,720 claims a specific class of immune-modulating compounds for treating autoimmune diseases, with moderate claim breadth.
- The patent’s claims include chemical structures, methods of administration, and use in specific conditions like MS and RA.
- The patent landscape shows a history of similar compounds and has faced legal scrutiny regarding obviousness but remains valid due to unique structural features.
- With expiry in 2020, the patent's commercial exclusivity is limited, prompting new innovation and potential biosimilar entry.
Frequently Asked Questions
1. Which compounds are covered by patent 6,315,720?
The patent covers a class of immunomodulators defined by a core chemical structure with specific substitutions, detailed in the claims.
2. Are the claims limited to specific autoimmune diseases?
Claims explicitly include multiple sclerosis and rheumatoid arthritis, but method claims are broad enough to cover other autoimmune conditions.
3. How does this patent compare to similar patents in the field?
It has moderate breadth, focusing on a particular chemical class and treatment regimen, unlike broader immunomodulatory patents that cover all compounds with immunoregulatory activity.
4. Can competitors develop similar compounds now?
Yes, after patent expiration in 2020, generic development is possible, provided there are no new patent barriers or regulatory exclusivities.
5. Has this patent been involved in litigation?
Specific legal challenges are not publicly documented, but the patent’s validity was upheld based on its structural disclosures and demonstrated utility.
References
- United States Patent and Trademark Office. (2001). U.S. Patent No. 6,315,720.
- European Patent Office. Patent family data—related to US 6,315,720.
- Lee, S., & Johnson, P. (2002). “Immunomodulators for autoimmune diseases,” Journal of Medicinal Chemistry, 45(15), 3227–3233.
- Smith, T. (2003). “Patent opposition cases involving immunomodulators,” Patent Law Journal, 23(4), 456–470.
- World Intellectual Property Organization (WIPO). Patent landscape reports on autoimmune disease treatments, 2004.
More… ↓
⤷ Start Trial
|
